Reliability and Validity of the Glittre Activities of Daily Living Test in Multiple Sclerosis Patients

February 9, 2021 updated by: Gözde KAYA, Hacettepe University

Patients with Multiple Sclerosis (MS) have reduced functional capacity due to clinical symptoms of the disease, resulting in decreased participation in daily living activities and reduced quality of life. Evaluation of functional capacity and activities of daily living is very important in order to determine appropriate rehabilitation programs and increase the participation of patients in daily life activities. However, although there are many scales evaluating functional capacity and activities of daily living in people with disabilities, there is no specific assessment scale specific to MS patients. Therefore, this study was planned to investigate whether the Glittre Daily Living Activities (ADL) Test, which was developed to measure functional capacity in chronic obstructive pulmonary disease, is a valid and reliable measurement tool in MS patients. For this purpose, a total of 51 participants (25 MS patients and 26 healthy participants) evaluated with Glittre ADL Test.

The relationship between Glittre ADL Test and 6-minute walk test, Notthingham Extended Daily Living Activities Index, Multiple Sclerosis Quality of Life Scale, Fatigue Severity Scale, Balance Assessment Systems Test (MiniBEST Test), Extended Disability Status Scale and 5-repetition sit-to-stand test evaluated with Pearson or Spearman correlation coefficient. For the known group validity, the difference between the patient and control groups compared with the test of the difference between the two means. For reliability, test retest performed. Reliability evaluated with the intraclass correlation coefficient.

Hypothesis 1: Glittre ADL Test results in MS patients and healthy subjects are different.

Hypothesis 2: Glittre ADL Test is reliable in MS patients.

Hypothesis 3: Glittre ADL Test is valid for evaluating functional exercise capacity in MS patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Multiple Sclerosis (MS) is a chronic, inflammatory disease characterized by demyelination, myelin damage, axonal loss and gliosis in the Central Nervous System (CNS). MS symptoms vary according to the size of the lesion and its location in the CNS. Clinical symptoms are generally: spasticity, fatigue, muscle weakness, tremor, pain, sensory disturbances, bladder bowel problems, cognitive disorders, depression and sleep disorders. With the progression of the disease, the performance in daily living activities gradually decreases, affecting the quality of life negatively. Maintaining aerobic capacity in chronic diseases such as MS is very important for independence in daily living activities. Functional exercise capacity of MS patients decreases with the effect of symptoms and sedentary lifestyle. The decrease in aerobic capacity can manifest itself with a decrease in walking distance or speed, or a limitation in daily living activities. Decline in aerobic capacity is also associated with many factors such as increased risk of cardiovascular disease, decreased cognitive functions and health-related quality of life. Therefore, aerobic capacity measurement is one of the important physiological measurements in terms of evaluating the existing functional status of individuals and preparing rehabilitation programs appropriately for individuals.

Cardiopulmonary exercise tests (CPET) are accepted as the gold standard in the evaluation of aerobic capacity. These measurements have some limitations that limit their use, such as the high cost of equipment and the need for a well trained team. Today, submaximal tests, questionnaires or scales are widely used as an alternative to CPET in evaluating functional exercise capacity. Since most daily life activities are at the submaximal level, submaximal tests can better determine the functional levels of individuals in daily living activities.

In order to evaluate functional capacity in Chronic Obstructive Pulmonary Disease (COPD), activities similar to daily life activities were selected and the Glittre Daily Living Activities (ADL) Test was developed. It has been shown that the Glittre ADL Test is reliable and valid in evaluating functional exercise capacity in COPD, as well as reflecting the performance in daily living activities for this disease group. The activities in the Glittre ADL Test are those that require the use of both the lower and upper extremities. An important advantage of the test is that the test can reflect functional capacity as well as providing information about performance in daily life activities and that the use of all extremities can be observed during the test.

In this study, the reliability and validity of the Glittre ADL Test in MS patients was investigated. For the criterion validity of the Glittre ADL Test, the correlation with the 6-minute walk test (6MWT) was examined. Patient and control groups were compared for known group validity. Test-retest method was used to determine the reliability of Glittre ADL Test. Intra-observer reliability was evaluated by intraclass correlation coefficient (ICC). The relationship between Glittre ADL Test scores and lower extremity muscle strength, limitation of daily living activities, balance, quality of life, fatigue and disease severity was investigated. Correlations between the time to complete the Glittre ADL Test and the 5 Repetition Sit To Stand Test completion time, Nottingham Extended Activities of Daily Living Scale, Mini Balance Evulation Systems Test, Multiple Sclerosis Quality of Life 54 scale, Fatigue Severity Scale and Expanded Disability Status Scale scores were examined.

Study Type

Observational

Enrollment (Actual)

51

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Ankara, Turkey
        • Hacettepe University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Volunteers of the patients who applied to Hacettepe University Neurology Department, diagnosed with MS by specialist physician and referred to Hacettepe University Faculty of Health Sciences Physiotherapy and Rehabilitation Department for physiotherapy and rehabilitation program were included in the study.

Description

Inclusion Criteria:

  • Between 18-65 years
  • Relapsing Remitting Multiple Sclerosis (RRMS) type MS disease.
  • Extended Disability Status Scale (EDSS) score of maximum 4.5
  • No attacks during the last 3 months
  • The medication has not been changed in the last 6 months.
  • Getting more than 24 points from the Standardized Mini Mental Test.

Exclusion Criteria

  • Having had any musculoskeletal surgery.
  • Using a walking aid or orthosis.
  • Having a neurological disease other than MS.
  • Having orthopedic or rheumatological problems that will affect function.
  • Having a peripheral vestibular problem.
  • Having a cardiovascular and pulmonary disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Study Group
Multiple Sclerosis Patients
Other: Measurement of functional exercise capacity
The Glittre Activities of Daily Living (ADL) Test was used to evaluate functional exercise capacity.
Control Group
Healthy Subjects
Other: Measurement of functional exercise capacity
The Glittre Activities of Daily Living (ADL) Test was used to evaluate functional exercise capacity.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glittre Activities of Dailiy Living Test
Time Frame: 10 minute
Functional exercise capacity measurement
10 minute

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
6 minute walk test (6MWT)
Time Frame: 10 minute
Functional exercise capacity measurement 6MWT was performed in accordance with American Thoracic Society guidelines. The start and end points of the test were determined. The test was carried out in a 30-meter corridor, avoiding distractions. 6-minute walking distance recorded in meters at the end of the test.
10 minute
Nottingham Extended Daily Living Activities Index (NGGYAI)
Time Frame: 10 minute
Nottingham Extended Daily Living Activities Index (NGGYAI) was used to evaluate the daily living activities. In addition to the Turkish validity and reliability of the index, it has been reported that it is reliable and valid in MS patients. The scale consists of 22 questions covering mobility, kitchen, home and entertainment activities. A higher score 0-66 scale indicates a better activities of daily living.
10 minute
Extended Disability Status Scale (EDSS)
Time Frame: minimum 30 minute

Expanded Disability Status Scale (EDSS) is the most commonly used scale to monitor disease stage and assess disability in multiple sclerosis patients.

Eight functional systems (FS) are evaluated with EDSS (Visual functions, brain stem functions, pyramidal functions, cerebellar functions, sensory functions, bladder and bowel functions, cerebral functions and other). In addition, gait is also evaluated and a score between 0 (normal neurological status) and 10 (death due to MS) is determined by considering functional system scores and the level of independence of the patient in ambulation.
minimum 30 minute
Fatigue Severity Scale
Time Frame: 10 minute

Fatigue severity scale was used to evaluate the severity of fatigue. The scale consists of 9 items.

Patients are asked to choose one of the options from 1 to 7 for each item in the scale.

The Fatigue Severity Scale score is calculated by averaging the scores of the answers given to the nine items. A high score indicates an increase in the severity of fatigue.
10 minute
Multiple Sclerosis Quality of Life İnstrument - 54 (MSQOL-54)
Time Frame: 15 minute

Multiple sclerosis quality of life instrument (MSQOL-54), which was developed for MS patients and was validated and reliable in Turkish, was used to evaluate the quality of life of the patients.

The scale consists of 14 subheading and 54 items. Each subheading is evaluated out of 100 points and 100 points represent the best status and 0 points represent the worst.

The scores of the patients according to their answers to each question are calculated under 14 subheading.

Then, with a separate calculation, according to the scores obtained from 14 subheading, 2 separate scores are obtained as physical and mental.
15 minute
Mini-BEST Test (Balance Assessment Systems Test)
Time Frame: 15-20 minute

Mini-BEST Test (Balance Assessment Systems Test) was used to evaluate the balance.

Mini-BESTest is the shortest version of BESTest. Test include 4 subheading named preparatory movement, reactive postural control, sensory orientation and dynamic gait. Each subheading has its own total scoring. The total score of preparatory movement, reactive postural control and sensory orientation was 6, and the total score of the dynamic walking subheading was 10 points. The highest score in the test is 28.

As the score decreases, the physical condition deteriorates. Each case tested has 3 points, 0-1-2, which are defined as severe, moderate and normal, respectively. One of these 3 points is selected based on the patient's performance in the tested condition.
15-20 minute
The 5-repetition sit-to-stand test
Time Frame: 10 minute

This test has been shown to provide information about lower extremity muscle strength in MS patients.

The 5-repetition sit-to-stand test is a measure of the time taken to complete five repetitions of the sit-to-stand movement.
10 minute

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hacettepe University

Investigators

  • Principal Investigator: Nezire KÖSE, Prof., Hacettepe University
  • Study Chair: Rana KARABUDAK, Prof., Hacettepe University
  • Study Chair: Meryem A TUNCER, Prof., Haceetepe University
  • Principal Investigator: Kadriye ARMUTLU, Prof., Hacettepe University
  • Principal Investigator: Yeliz SALCI, Asts. Prof., Hacettepe University
  • Principal Investigator: Jale KARAKAYA, Assoc. Prof., Hacettepe University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2018

Primary Completion (Actual)

October 15, 2019

Study Completion (Actual)

August 4, 2020

Study Registration Dates

First Submitted

November 26, 2019

First Submitted That Met QC Criteria

November 27, 2019

First Posted (Actual)

December 2, 2019

Study Record Updates

Last Update Posted (Actual)

February 12, 2021

Last Update Submitted That Met QC Criteria

February 9, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Hacettepe UN

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on Measurement of functional exercise capacity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe